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Some histone deacetylases (HDACs) promote tumor cell growth and pan- or selective HDAC 
inhibitors are active in some cancers, however, the pivotal HDAC enzyme and its functions in 
human diffuse large B-cell lymphoma (DLBCL) remain largely unknown. Using NanoString 
nCounter assays, we profiled HDAC mRNA expression and identified HDAC6 as an 
upregulated HDAC family member in DLBCL tissue samples. We then found that HDAC6 
plays an oncogenic role in DLBCL, as evidenced by its promotion of cell proliferation in 
vitro and tumor xenograft growth in vivo. Mechanistically, the interaction between HDAC6 
and HR23B downregulated HR23B expression, thereby reducing the levels of casitas 
B-lineage lymphoma (c-Cbl), an E3 ubiquitin ligase for hepatocyte growth factor receptor 
(MET), which resulted in the inhibition of MET ubiquitination-dependent degradation. In 
addition, enhanced HDAC6 expression and decreased HR23B expression were correlated 
with poor overall survival rates among patients with DLBCL. Taken together, these results 
establish an HDAC6-HR23B-MET axis and indicate that HDAC6 is a potent promoter of 
lymphomagenesis in DLBCL. Thus, a therapeutic strategy based on HDAC6 inhibitors in 
combination with MET inhibitors is promising.  
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The pathogenesis of human diffuse large B-cell lymphoma (DLBCL) is complex and 
heterogeneous, and the potential pathogenic mechanisms have not been fully elucidated [1]. 
In addition to genetic and genomic alterations, histone deacetylation, CpG methylation and 
histone hypermethylation contribute to chromatin remodeling/condensation and 
transcriptional inhibition of target genomic regions [2, 3]. Notably, histone deacetylases 
(HDACs) affect the transcription of many suppressor genes and oncogenes involved in cell 
proliferation, apoptosis, survival, differentiation, and genetic stability [4]. Histone 
modification changes are common in human malignancies, including DLBCL [5-7]. 
Inhibition of HDAC activity exerts potent in vitro antitumor effects and slows tumor 
xenograft growth in vivo [8,9]. Therefore, HDAC family members have become promising 
therapeutic targets.  
    Histone deacetylase 6 (HDAC6) is involved in the aggresomal degradation of 
ubiquitinated proteins and contributes to the sensitivity of HDAC inhibitors (HDACi) [9]. 
Deletion of HDAC6 delayed disease progression in an SOD1G93A mouse model of 
amyotrophic lateral sclerosis [10]. Additionally, HDAC6 deficiency has been shown to 
significantly suppress cell proliferation and prolong tumor xenograft growth in ovarian and 
prostate cancers [8,9]. Some studies have described the expression of HDAC6 in B- and 
T-cell lymphomas [5-7], although its clinical significance and functional role in 
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lymphomagenesis and subsequent progression remain largely unknown. A recent study 
revealed that HDAC6 downregulates HR23B by interacting with it, thereby inducing the 
apoptosis of desensitizing cells by decreasing the levels of ubiquitinated substrates that are 
targeted to the proteasome [11]. HR23B (encoded by RAD23B), which has been previously 
identified as a biomarker in response to HDACi [12-14], can function as a tumor suppressor 
[15]. Furthermore, HR23B targets gene promoters, which implies that HR23B might be 
involved in transcriptional regulation [16]. Hence, the function of HR23B in mediating 
HDAC6 to regulate its downstream signaling should be further explored.  
    Hepatocyte growth factor receptor (MET) is involved in various biological processes, 
including cell proliferation, migration, invasion and dissemination, in many human cancers 
[17-20]. MET has been found to be overexpressed in patients with DLBCL and correlated 
with upregulation of phosphorylated Akt (p-Akt) and phosphorylated GSK3 (p-GSK3); in 
vitro, MET inhibition by either pharmacological or genetic means leads to caspase-dependent 
apoptosis [17]. Studies of MET signaling in hepatocellular carcinoma (HCC) have revealed 
that MET tyrosine kinase signaling is regulated and hyperactivated by HDACs through 
microRNA-449 inhibition [3]. However, the relationship between HDACs and MET 
signaling and alternative mechanisms have not been investigated in DLBCL. 
    Ricolinostat is the first oral selective HDAC6 inhibitor with reduced class I HDAC 
activity to be studied clinically, and it might partner well with other compounds to enhance 
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their efficacies in treating diverse cancers. Although the results from experimental or 
preclinical studies have shown that combinations of ricolinostat with lenalidomide, ibrutinib, 
carfilzomib or bortezomib can exerts synergistic effects in multiple myeloma, DLBCL and 
mantle cell lymphoma [21-26], the combination of ricolinostat with a MET inhibitor (METi) 
has not been investigated in DLBCL. 
    Based on the aforementioned observations, we aimed to determine whether HDAC6 
plays a key role in lymphomagenesis and whether HR23B is essential for HDAC6-mediated 
regulation of MET signaling in DLBCL. 
 
Materials and methods   
 
Patient samples 
After obtaining approval from the institutional review boards and the local ethical 
committees from the authors’ institutions, 87 fresh-frozen and 151 paraffin-embedded tumor 
biopsy samples from patients with DLBCL, along with 12 fresh-frozen and 20 
paraffin-embedded non-tumor lymphoid tissue samples from individuals who were diagnosed 
with reactive lymphoid hyperplasia (RLH), were collected from Fudan University Shanghai 
Cancer Center (Shanghai, China). Informed consent was obtained from the participants who 
provided specimens. DLBCL was identified as the germinal center B-cell (GCB) or the 
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activated B-cell (ABC) subtype based on the Hans immunohistochemistry (IHC) algorithm 
for fresh/frozen paraffin-embedded tumor biopsies [27,28]. The RLH samples, including 
tonsils and lymph nodes, were obtained from individuals who underwent tonsillectomies or 
lymph node biopsies. For HDAC expression profiling in DLBCL, total RNA was isolated 
from 24 enriched DLBCL frozen tumor tissues and 10 tonsil tissues and was subjected to 
NanoString nCounter assays. HDAC6 mRNA expression was further detected in a larger 
validation cohort of 87 DLBCL and 12 RLH samples, including the discovery cohort, by 
using RT-qPCR. Representative histological FFPE blocks of 151 DLBCL tumor biopsies, 
including 58 DLBCL samples from the above validation cohort and 20 RLH samples, were 
subjected to IHC analysis. 
 
NanoString nCounter assay 
HDAC expression profiling was conducted for 24 enriched DLBCL tumor samples and 10 
tonsil samples using NanoString nCounter assays (NanoString Technologies, Seattle, WA, 
USA) with a panel of custom-compiled gene probes, including total HDACs (HDAC1-11 and 
SIRT1-7). The custom array contained 18 gene probes with three “housekeeping” reference 
genes (ALAS1, B2M and CLTC), which were used as the internal controls (supplementary 
material, Table S1). A NanoString assay was performed as previously described [29]. For a 
detailed description, see supplementary material, Supplementary materials and methods.  
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A NanoString nCounter assay was also performed to investigate the potential 
signaling downstream of HDAC6, as described above. Based on a comprehensive review of 
the most recent and most significant references, we designed a library containing the 79 
genes found in several pivotal pathways that might play key roles in the initiation, 
progression and therapeutic target development of DLBCL in addition to three reference 
genes by generating a probe array (supplementary material, Table S1).  
 
Cell lines and lentiviral infection  
NuDUL1, SuDHL-2 and SuDHL-4 cells were purchased from the American Type Culture 
Collection (ATCC, USA). OCI-LY1, OCI-LY8 and OCI-LY10 were kindly provided by Dr. B. 
Hilda Ye (Albert Einstein College of Medicine, NY, USA), and the DoHH2 cells were a gift 
from Prof. Mingzhi Zhang (the First Affiliated Hospital of Zhengzhou University, Zhengzhou, 
China). Toledo cells were provided as a gift from Dr. Thomas Wu (Sundia MediTech, 
Shanghai, China). All cell lines were authenticated through short tandem repeat profiling at 
SIBS (Shanghai, China) and tested for mycoplasma infection using the Universal 
Mycoplasma Detection Kit (ATCC). Generation of cells stably transfected with lentivirus was 
performed (supplementary material, Supplementary materials and methods). 
 
RT-qPCR 
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Total RNA was isolated using a TRIzol kit (Invitrogen, Grand Island, NY, USA) and purified 
with an RNeasy Plus Kit (Qiagen, San Diego, CA, USA). cDNA was synthesized with the 
M-MLV Reverse Transcriptase Kit (Invitrogen). Then, qPCR was performed using SYBR 
GREEN according to a standard protocol (Takara, Shiga, Japan). For a detailed description, 
see supplementary material, Supplementary materials and methods.  
 
Histological and cytological staining  
Histological processing and staining and immunofluorescence (IF) staining were performed 
as described previously [18] and in supplementary material, Supplementary materials and 
methods.  
    Using a histological scoring system, the results of IHC for HDAC6 and HR23B were 
determined. Both staining intensity and the proportion of positive tumor cells were taken into 
account. Briefly, a proportional score of 0 to 4 was assigned for the proportion of positive 
cells (0, no positive cells; 1, ≤ 25% positive cells; 2, 26~50% positive cells; 3, 51~75% 
positive cells; 4, > 75% positive cells). An intensity score of 0 to 3 was assigned for the 
intensity of positive cells (0, none; 1, weak; 2, intermediate; 3, strong). The final score was 
clustered into four groups: “-” denotes ≤ 2 total points; “+” denotes 3-4 total points; “++” 
denotes 5-6 total points; “+++” denotes 7 total points. Additionally, “-” and “+” are defined 
as low expression, whereas “++” and “+++” are defined as high expression [14].  




Western blot and immunoprecipitation (IP) 
Frozen human DLBCL tissues or harvested cells were lysed with RIPA lysis buffer. Western 
blot and IP assays were performed as described previously [18]. Details of primary and 
secondary antibodies are shown in supplementary material, Table S2.  
 
Cell proliferation and apoptosis  
Cell number was monitored using a Cell Counting Kit-8 (CCK8; Dojindo, Kumamoto, Japan) 
according to the manufacturer’s instructions. Apoptosis was detected using a dual staining 
Annexin V/PE-7AAD Apoptosis Detection kit (BD Biosciences, San Diego, CA, USA) and a 
Cytomics FC500 flow cytometer (Beckman Coulter, Brea, CA, USA). The percentage of 
apoptotic cells in each quadrant was analyzed using CXP Software (Beckman Coulter). Each 
experiment was performed in triplicate.  
 
Tumor xenograft models 
The animal studies were performed under the guidelines approved by the Animal Ethics 
Boards of Fudan University Shanghai Cancer Center. We established animal models based on 
previous studies [30-32]. In brief, female 6-week-old BALB/c nude mice were randomly 
assigned to four groups (n = 6 per group) and anesthetized through intraperitoneal (i.p.) 
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injection of ketamine (100 mg/kg). Subsequently, the mice were injected subcutaneously (s.c.) 
with 2 × 106 NuDUL-1 cells infected with either Lenti-shHDAC6 or negative control (NC) in 
0.05 ml of PBS or injected with OCI-LY8 cells infected with either Lenti.HDAC6 or NC in 
0.05 ml of PBS. The tumor volumes were estimated by measuring two dimensions (length [L] 
and width [W]), and the volume was calculated as V = LW2 / 2. Finally, the tumors were 
excised and frozen in liquid nitrogen or fixed in 4% neutral paraformaldehyde solution for 
Western blot or IHC analyses, respectively.  
    Additionally, NuDUL-1 cells without any treatment were injected into 24 mice, and 
when the tumors reached 68–185 mm3, the mice were randomly assigned to four groups (n = 
6 per group). We intraperitoneally treated the mice every other day with the vehicle (DMSO), 
with crizotinib and ricolinostat (Selleck Chemicals; 50 mg per kg body weight) through daily 
oral gavage [22,33], or with the ricolinostat/crizotinib combination for 18 d. In addition to 
tumor volume estimation, the tumor doubling time (DT) and tripling time (TT) were 
calculated. For all procedures (implantation and chemotherapy), the mice were anesthetized 
with an i.p. injection of ketamine/xylazine (87/13 mg/ml) at 1 ml/kg. For implantation, the 
mice were anesthetized with an i.p. injection of ketamine/xylazine (87/13 mg/ml) at 1 ml/kg. 
Finally, all mice were euthanized by cervical dislocation under anesthesia.  
 
Statistical analysis 
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The statistical analyses were performed using GraphPad Prism v 7.0 (GraphPad Software, La 
Jolla, CA, USA). The data, presented as the means ± SDs, were analyzed using unpaired 
two-tailed Student’s t-tests or one-way analysis of variance (ANOVA). Kaplan-Meier 
survival curves were plotted, and a log-rank test was performed. For drug-synergy assessment, 
the combination index (CI) was calculated using CompuSyn v 1.0 (ComboSyn, Paramus, NJ, 




HDAC6 is differentially expressed in DLBCL tissues and associated with poor prognosis 
Using NanoString nCounter assays, we identified HDAC1 and HDAC6 as the top two 
differentially expressed HDAC mRNAs in 24 DLBCL patient samples, while HDAC6 
expression was five-fold higher in the 24 DLBCL tissues than in the 10 tonsil tissues (Figure 
1A). To validate this finding, RT-qPCR was performed using 87 DLBCL and 12 RLH 
samples, including the samples tested by NanoString nCounter assays. Consistently, HDAC6 
mRNA expression was significantly higher in the DLBCL tissues than in the RLH tissues (p 
< 0.05; Figure 1B). Western blot analysis established that HDAC6 protein expression was 
higher in DLBCL than in RLH (Figure 1C). IHC analysis of 151 DLBCL samples revealed 
that HDAC6 was localized in the perinuclear/cytoplasmic region and was differentially 
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expressed in DLBCL; however, HDAC6 expression was primarily limited to germinal centers 
(GCs) in RLH samples (Figure 1D). The IHC revealed that high HDAC6 expression was 
found in 32% (48/151) of the DLBCL samples, which was significantly more frequently than 
in the RLH samples (10%, 2/20) (p < 0.05, Figure 1E). Meanwhile, the expression levels of 
HDAC6 were comparable between NanoString and RT-qPCR (p < 0.05, supplementary 
material, Figure S1A) and between RT-qPCR and IHC (p < 0.05). However, no significant 
correlation between the results from NanoString and IHC was observed (p > 0.05), which 
could be due to the limited overlapping samples.  
    The clinicopathological features of 151 DLBCL samples grouped by HDAC6 protein 
expression levels as determined by IHC are summarized in supplementary material, Table S3. 
High HDAC6 protein expression (HDAC6high) was associated with tumor stage progression 
(p < 0.05). Kaplan-Meier survival curves, with a median follow-up of 30 months, 
demonstrated that the overall survival (OS) of DLBCL patients bearing tumors with 
HDAC6high was substantially lower than that of DLBCL patients bearing tumors with low 
HDAC6 protein expression (HDAC6low) (p < 0.001, Figure 1F). Multivariate Cox regression 
analysis revealed that high HDAC6 expression was associated with poor prognosis in 
DLBCL (hazard ratio, 3.48; p < 0.001), and HDAC6 is an independent prognostic factor in 
DLBCL (supplementary material, Table S4).  
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HDAC6 knockdown arrests cell proliferation and triggers cell cycle arrest and apoptosis in 
DLBCL cells 
Given the correlation of high HDAC6 expression with poor prognosis in DLBCL, we sought 
to explore the functional impact of HDAC6 in DLBCL cells. Western blot analysis showed 
that HDAC6 was highly expressed in all non-GCB/ABC-subtype cell lines (NuDUL-1, 
OCI-LY10 and SuDHL-2 cells) and in one GCB-subtype cell line, Toledo cells (Figure 2A). 
NuDUL-1 and Toledo cells were infected with Lenti-shHDAC6, while Lenti-HDAC6 
infection was performed in OCI-LY1 and OCI-LY8 cells with lower basal HDAC6 
expression. Knockdown of HDAC6 in NuDUL-1 and Toledo cells significantly abrogated 
cell proliferation, whereas overexpression of HDAC6 in OCI-LY1 and OCI-LY8 cells 
revealed opposite effects (Figure 2B). A fluorescence-activated cell sorting (FACS) analysis 
revealed that knockdown of HDAC6 induced a significant increase in early apoptosis in 
NuDUL-1 and Toledo cells, whereas HDAC6 overexpression did not induce significant 
opposite effects (Figure 2C). Consistently, knockdown of HDAC6 in NuDUL-1 and Toledo 
cells resulted in increased cleaved PARP and cleaved caspase-9, -8, and -3 expression (Figure 
2D), whereas except for a reduction in cleaved PARP expression observed in OCI-LY8 cells 
with HDAC6 overexpression, no obvious changes in the protein levels were found in 
OCI-LY1 or OCI-LY8 cells with HDAC6 overexpression (supplementary material, Figure 
S1B). Similarly, knockdown HDAC6 in NuDUL-1 and Toledo cells led to significant cell 
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arrest in the G2/M phase (Figure 2E), whereas HDAC6 overexpression did not induce 
opposite effects in OCI-LY1 or OCI-LY8 cells (supplementary material, Figure S1C). 
Changes in the representative regulatory proteins involved in cell cycle progression, 
including cyclin E1, CDK6, cyclin B1, p27 and p21, supported our findings by FACS 
analysis (Figure 2F; supplementary material, Figure S1D). 
 
HDAC6 activates MET signaling in DLBCL 
We sought to investigate the potential signaling pathways regulated by HDAC6. Using 
NanoString nCounter assays, we evaluated mRNA changes in selected genes associated with 
several pivotal signaling pathways (in terms of the initiation, progression and therapeutic 
target development of DLBCL) in stable HDAC6-downregulated NuDUL-1 cells. Genes 
associated with the HGF/MET pathway were significantly regulated in the 
HDAC6-knockdown groups compared to control groups (Figure 3A). We therefore evaluated 
MET protein expression in 151 DLBCL samples by IHC; MET was primarily localized on 
the cell membrane (Figure 3B) and was significantly increased in DLBCL tissues (28%, 
42/151) compared to RLH tissues (10%, 2/20, Figure 3C). Increased HDAC6 and MET 
expression levels were found in some DLBCL samples by IHC, although no significant 
correlation was observed in the 151 DLBCL samples (p > 0.05). Western blot (Figure 3D) 
and IF (Figure 3E) analyses revealed that MET expression was decreased in the 
This article is protected by copyright. All rights reserved.
 
 17 
HDAC6-downregulated NuDUL-1 and Toledo cells, whereas upregulation of HDAC6 in 
OCI-LY8 and OCI-LY1 cell lines produced opposite effects. Moreover, MET protein 
expression was significantly reduced in NuDUL-1 and Toledo cells treated with ricolinostat 
as determined by FACS analysis (p < 0.001, supplementary material, Figures S2A, B). MET 
is known as a potent activator of the PI3K/Akt and Ras/MAPK pathways and the NF-º B 
cascades [18]; therefore we measured total and phosphorylated protein expression levels of 
several members of these pathways. Knockdown of HDAC6 in NuDUL-1 and Toledo cells 
resulted in downregulation of phosphorylated Akt, NF-º B and Erk1/2, whereas 
phosphorylated NF-º B1 and NF-º B2 levels remained unaffected (Figure 3F).  
 
HR23B deficiency mediates MET activation by HDAC6 
In addition to serving as a response biomarker to HDACi, HR23B is a downstream regulator 
of HDAC6 [11]. Western blots and IF confirmed the correlation between HDAC6 and 
HR23B, and IP revealed that HR23B directly interacts with HDAC6 (supplementary material, 
Figures S3A-C). We therefore hypothesized that HR23B might mediate the activation of 
MET by HDAC6. By infecting NuDUL-1 and OCI-LY8 cells with Lenti-shHR23B and 
Lenti-HR23B, respectively, we accordingly observed upregulation and downregulation of 
MET protein by Western blot and IF (Figures 4A, B). Furthermore, HDAC6 knockdown 
increased HR23B and reduced MET expression in the DLBCL cells, whereas overexpression 
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of HDAC6 produced the opposite effect, as shown by the Western blot (Figure 4C). Previous 
studies have shown that casitas B-lineage lymphoma (c-Cbl), an E3-ubiquitin ligase for MET, 
plays a key role in regulating MET ubiquitination-dependent degradation [33,34]. Thus, we 
investigated whether HR23B deficiency caused c-Cbl downregulation by assessing the levels 
of c-Cbl and global ubiquitination in HR23B-knockdown cells and in cells overexpressing 
HR23B. The knockdown of HR23B in NuDUL-1 cells resulted in lower levels of c-Cbl and 
global ubiquitination expression than those in the control cells, and the opposite effects were 
observed in HR23B-overexpressing OCI-LY8 cells (Figure 4D). 
    In addition, we assessed HR23B expression in 151 DLBCL clinical tissue samples using 
IHC. HR23B was differentially expressed in DLBCL and was scored as “low” or “high” 
(Figure 4E). The frequency of high HR23B expression (68%, 103/151) in DLBCL tissues 
was significantly lower than that in RLH tissues (95%, 19/20) (p < 0.05, Figure 4F). 
Significant associations were found between low HR23B expression and more aggressive 
phenotypes (high International Prognostic Index [IPI] scores and ABC type; supplementary 
material, Table S3). Kaplan-Meier survival curves revealed a lower OS rate for DLBCL 
patients with HR23B deficiency (p < 0.05, Figure 4G), although multivariate Cox regression 
analysis showed that HR23B expression was not an independent prognostic factor for 
DLBCL (data not shown). As indicated by IHC and Western blot analyses, HDAC6 
expression was negatively correlated with HR23B expression in the 151 DLBCL samples 
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(supplementary material, Figures S4A-C, r = -0.375, p < 0.001). Furthermore, HR23B 
expression was significantly positively correlated with MET expression in the 151 DLBCL 
samples (p < 0.05). 
 
MET inhibition increased the inhibitory effect induced by HDAC6i in DLBCL cells 
The aforementioned findings established an HDAC6-HR23B-MET axis, which led us to 
evaluate the combinatorial effect of inhibitors targeting HDAC6 and MET in DLBCL. 
Through Lenti-shHDAC6 and Lenti-shMET transfection, we first determined that the 
knockdown of MET increased the inhibitory effects of the HDAC6 knockdown in NuDUL-1 
and Toledo cells (Figure 5A). We then selected ricolinostat and crizotinib, a potent inhibitor 
of MET, for treating HDAC6high NuDUL-1 and Toledo cells. The IC50 values of ricolinostat 
and crizotinib were determined from dose-response studies using CCK8 assays. The single 
treatment with ricolinostat or crizotinib showed moderate efficacy in both NuDUL-1 and 
Toledo cells (Figure 5B), whereas another METi, PF-04217903, was not active in either 
DLBCL cell line (supplementary material, Figure S5). FACS analysis showed that 
ricolinostat induced apoptosis in DLBCL cells, which was also supported by Western blot 
analysis (Figures 5C and 5D). Importantly, compared with the effects of either inhibitor alone, 
the combination of ricolinostat and crizotinib exerted potent inhibition on DLBCL cell 
growth and generated strong synergistic effects (CI values < 1.0, Figures 5E and 5F). The 
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combination treatment induced apoptosis of NuDUL-1 and Toledo cells, as was also 
demonstrated by increased PARP cleavage and caspase-3 cleavage (Figures 5G and 5H). 
Moreover, the combination reduced the level of phosphorylated MET (Figure 5H).  
 
HDAC6 facilitated lymphomagenesis, and ricolinostat in combination with crizotinib 
generated a synergistic effect on DLBCL in vivo 
Consistent with the in vitro findings, the knockdown of HDAC6 significantly arrested 
NuDUL-1 DLBCL xenograft growth by reducing the tumor size up to 85.5% compared with 
the NC (p < 0.001; Figure 6A). Staining for the proliferation marker Ki-67 also revealed 
significantly decreased expression in tumor cells (Figure 6B), whereas compared with the NC 
condition, HDAC6 overexpression increased OCI-LY8 xenograft growth by ~4.15-fold and 
increased Ki-67 expression (Figures 6C and 6D).  
    Subsequently we examined the in vivo efficacy of ricolinostat combined with crizotinib 
using a human DLBCL xenograft mouse model. The growth delay (GD) obtained with the 
combination of inhibitors was significantly longer than that observed in the groups treated 
with each inhibitor alone (DT, p < 0.01; TT, p < 0.01, Figure 6E). Crizotinib (50 mg/kg) and 
ricolinostat (50 mg/kg) modestly suppressed tumor growth by ~47% and ~62%, respectively, 
compared with DMSO treatment. Moreover, the combination treatment significantly 
inhibited tumor growth by ~87% (crizotinib/ricolinostat; Day 28, p < 0.001; Figure 6F). In 
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addition to GD and tumor size, we also assessed the effects of the treatments on total and 
phosphorylated MET protein expression and the expression of the proliferation marker Ki-67 
(Figure 6G, supplementary material, Figure S6), which confirmed our in vitro findings. Taken 
together, the findings suggest that the combination of crizotinib and ricolinostat is a 
promising therapeutic strategy for DLBCL. 
 
Discussion 
HDAC6, a class IIb HDAC, acts as a deacetylase of ±-tubulin and other cytoplasmic proteins 
(e.g., HSP90 and cortactin) [35,36]. HDAC6 plays critical roles in transcription regulation, 
cell cycle progression and tumor cell survival. Its selective inhibitors have been enrolled into 
clinical trials; however, the functions of HDAC6 in tumors remain controversial. Through 
activation of the JNK/c-Jun pathway, leading to autophagic cell death, or via suppression of 
NF-º B p65 nuclear translocation, causing inactivation of NF-º B signaling, HDAC6 has been 
characterized as a tumor suppressor in HCC [37]. Interestingly, high levels of HDAC6 
mRNA and protein predict a better prognosis in patients with breast cancer, but forced 
expression of HDAC6 significantly increased cell motility and cell migration in breast cancer 
cells (MCF-7) [38, 39]. In a recent study, HDAC6 decreased cell migration and invasion 
abilities via deacetylation of heat-shock protein 5 (HSPA5), a marker of poor prognosis that 
promotes drug resistance and metastasis, at lysine residue 353 (K353) in breast cancer cells 
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[40]. Our findings demonstrate that HDAC6 plays an oncogenic role in DLBCL via indirect 
activation of MET signaling. Several reports have shown that HR23B can be used as a 
biomarker in response to HDACi; however, some studies have suggested a potential role for 
HR23B as a tumor suppressor in cancer progression. To date, little is known about the 
functions and mechanisms of HR23B in the initiation and subsequent progression of human 
malignancies. Recently, a novel function of HR23B was revealed: targeting gene promoters 
and performing transcriptional regulation [16]. The data presented here validate HR23B as a 
tumor suppressor-like factor that is inactivated by HDAC6 in DLBCL. Moreover, we found 
that decreased HR23B expression could serve as a prognostic factor in DLBCL, which is 
consistent with a previous study of breast cancer [15]. The results also confirmed that forced 
expression of HR23B inhibits cell proliferation and triggers apoptosis in vitro, suggesting that 
HR23B supports the tumor-suppressing role of HR23B in DLBCL. In this study, we first 
identified HR23B as a modulator of MET signaling. HR23B knockdown substantially 
upregulated MET expression, which is consistent with the effect induced by HDAC6 
overexpression. HR23B is involved in ubiquitination-dependent degradation, and several 
previous reports have suggested that MET ubiquitination can be mediated by c-Cbl 
[33,34,41]. Therefore, we hypothesized that HR23B regulates c-Cbl and influences MET 
ubiquitination. We confirmed that HR23B upregulates c-Cbl, resulting in increased 
ubiquitination levels and reduced MET levels. 
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    Despite the increasing knowledge base of genomic and transcriptomic abnormalities, a 
major clinical challenge persists: approximately 40% of patients with DLBCL receiving 
standard therapy of rituximab plus cyclophosphamide, doxorubicin, vincristine, and 
prednisolone (R-CHOP) are not cured [42]. To conquer this challenge, multiple targeted 
drugs have been developed and tested with one agent alone or in combination with other 
agents in clinical trials. Notably, the HDAC family, as the most important epigenetic modifier 
family, is responsible for chromatin remodeling, and has attracted considerable attention as a 
therapeutic target [3]. Similarly, most inhibitors or reagents, including those that inhibit 
HDAC or MET, those that are used for DLBCL treatment have shown limited efficacy when 
used alone, whereas their combination with other drugs might exert a synergistic antitumor 
effect [43-45]. After validating the efficacy of the combined ricolinostat and crizotinib 
treatment in vitro, we confirmed that the combination inhibits DLBCL xenograft growth in 
vivo.  
    Taken together, our findings demonstrate that HDAC6 plays an oncogenic role in 
DLBCL pathogenesis and could serve as a prognostic marker for DLBCL. The established 
HDAC6-HR23B-MET axis is associated with the oncogenic function of HDAC6 and 
provides a rationale for the use of ricolinostat and crizotinib combination treatment for 
patients with DLBCL. 
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Figure 1. HDAC profiling identified HDAC6, a predictor of poor prognosis in DLBCL. (A) 
Heat map of the expression patterns of HDAC mRNAs (HDAC1-11 and Sirt1-7) in 24 
DLBCL and 10 RLH (tonsil) tissues, as detected through a NanoString nCounter assay. The 
relative enhancement of HDAC mRNA expression is indicated through a red-to-blue color 
gradient. (B) Further validation of HDAC6 mRNA expression in 87 DLBCL and 12 RLH 
samples by RT-qPCR. Two-tailed Student’s t test: * p < 0.05. (C) Representative Western 
blots showing HDAC6 expression in lysates from freshly collected DLBCL and RLH tissues. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a loading control. (D) 
Representative HDAC6 immunostaining in paraffin-embedded DLBCL tumor samples (scale 
bar = 20 μm) and RLH samples (scale bar = 20 μm). “GC” refers to germinal center. (E) 
Frequency of HDAC6 protein expression in 20 RLH tissues and 151 DLBCL tissue samples. 
Two-sided Chi-squared test: * p < 0.05. (F) Kaplan-Meier survival curves for patients with 
DLBCL and low expression (n = 103) and high expression (n = 48) of HDAC6 protein. RLH, 
reactive lymphoid hyperplasia. Two-sided log-rank test: p < 0.001. Error bars show SD. 
 
Figure 2. Potential oncogenic role of HDAC6 in DLBCL. (A) The baseline of HDAC6 
protein expression in eight DLBCL cell lines was determined through Western blot analysis. 
GAPDH was used as a loading control. (B) The proliferation of NuDUL-1 and Toledo cells 
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after infection with Lenti-shHDAC6 and OCI-LY1 and OCI-LY8 cells after infection with 
Lenti.HDAC6 was determined by CCK8 assays. The p value for each time point was 
calculated using a two-tailed Student’s t test. * p < 0.05, ** p < 0.01, *** p < 0.001. (C) 
Assessment of apoptosis by Annexin V/PE-7AAD dual staining in NuDUL-1 and Toledo 
cells subjected to Lenti-shHDAC6 infection or OCI-LY1 and OCI-LY8 infected with 
Lenti.HDAC6 for 48 h. Each experiment was repeated three times. The p values were 
calculated using a two-tailed Student’s t test. ** p < 0.01, *** p < 0.001. (D) The cleavage of 
PARP, caspase-3, caspase-8 and caspase-9 were detected in cells transduced with 
Lenti-shHDAC6 by Western blot analysis. GAPDH served as loading control. (E) Analysis of 
cell cycle progression by propidium iodide (PI) staining in indicated cells infected with 
Lenti-shHDAC6 and Lenti.HDAC6. Each experiment was repeated three times. (F) Western 
blot analyses of the levels of cyclin E1, CDK6, cyclin B1, P27 and P21 in NuDUL-1 and 
Toledo cells subjected HDAC6 knockdown or NC. GAPDH served as loading control. NC = 
negative control. CCK8 = Cell Counting Kit-8. 
 
Figure 3. HDAC6 activates MET signaling in DLBCL. (A) A NanoString nCounter assay 
was used for pathway analysis between NuDUL-1 cells infected with Lenti-shHDAC6 and 
the NC. (B) Representative MET immunostaining in paraffin-embedded DLBCL tumor 
samples (scale bar = 20 μm) and RLH tissues (scale bar = 20 μm). The results were 
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determined by two pathologists who were both blinded to identifying information. The 
definition of “Low” or “High” expression was based on Uddin’s work [17]. (C) Proportions 
of MET protein expression in RLH and DLBCL tissues. Two-sided chi-squared test: * p < 
0.05. (D) Extracts prepared from indicated cells infected with Lenti-shHDAC6 or 
Lenti.HDAC6 were assessed by Western blot analysis for MET protein. GAPDH served as a 
loading control. (E) Immunofluorescence of MET in stable HDAC6 shRNA-expressing or 
HDAC6-overexpressing cells. The localization and levels of MET expression were detected 
using a Leica TCS SP5 laser-scanning confocal microscope (scale bar = 25 μm). Cells were 
counterstained with DAPI (blue) for nuclear staining. (F) Western blot analysis for total and 
phosphorylated Akt, Erk1/2, NF-º B2, and NF-º B1 in lysates from NuDUL-1 and Toledo 
cells infected with Lenti-shHDAC6 and NC. GAPDH served as a loading control. 
 
Figure 4. HR23B deficiency mediates MET activation by HDAC6. (A) Representative 
Western blots for HR23B and MET in NuDUL-1 and OCI-LY8 cells infected with 
Lenti-shHR23B and Lenti.HR23B, respectively. (B) Immunofluorescence staining for MET 
in stable HR23B shRNA-expressing NuDUL-1 cells and HR23B-overexpressing OCI-LY8 
cells was analyzed using a Leica TCS SP5 laser-scanning confocal microscope (scale bar = 
25 μm). The cells were counterstained with DAPI (blue) for nuclear staining. (C) 
Representative Western blots for HDAC6, HR23B and MET in NuDUL-1, and OCI-LY8 
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cells infected with Lenti-shHDAC6 and Lenti.HDAC6, respectively. (D) Lysates from cells 
treated with Lenti-shHDAC6 or Lenti.HR23B and NC were analyzed by Western blot with 
anti-c-Cbl, anti-Ub, and anti-MET antibodies for the detection of c-Cbl, ubiquitination and 
MET, respectively. NC = negative control. Ub = ubiquitin. (E) Immunostaining for HR23B in 
20 RLH tissues and 151 DLBCL tissue samples. Two-sided Chi-squared test: * p < 0.05. (F) 
Proportions of HR23B protein expression in RLH and DLBCL tissues. Two-sided 
Chi-squared test: * p < 0.05. (G) Kaplan-Meier survival curves for patients with DLBCL and 
low and high expression of HR23B protein. Two-sided log-rank test: p < 0.05. 
 
Figure 5. MET inhibition increases the inhibitory effects triggered by HDAC6 suppression in 
vitro. (A) Cell proliferation in NuDUL-1 and Toledo cells infected with Lenti-shHDAC6, 
Lenti-shMET or both was monitored by CCK8 assays. ** p < 0.01, *** p < 0.001. (B) 
Calculation of IC50 values for ricolinostat and crizotinib in NuDUL-1 and Toledo cells based 
on CCK8 assays. (C) Assessment of apoptosis by Annexin V/PE-7AAD dual staining of cells 
treated with ricolinostat. Vehicle was compared with ricolinostat using two-tailed Student’s t 
test: * p < 0.05. Each experiment was repeated three times. (D) Extracts prepared from 
NuDUL-1 and Toledo cells treated with ricolinostat were analyzed by Western blotting with 
anti-PARP or anti-cleaved caspase-3 (C-caspase-3) antibodies. GAPDH served as a loading 
control. (E) Cell proliferation of NuDUL-1 cells treated with ricolinostat (1 μM), crizotinib 
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(13 μM), or both, and of Toledo cells treated with ricolinostat (2.5 μM), crizotinib (75 μM), 
or both was monitored through CCK8 assays. One-way ANOVA: * p < 0.05. (F) Calculation 
of the combination index (CI) values for each pair of concentrations with fixed molar-ratio 
combinations of ricolinostat and crizotinib in NuDUL-1 cells and Toledo cells. (G) Using the 
identical drug concentrations described above, the assessment of apoptosis was performed 
through Annexin V/PE-7AAD dual staining of cells treated with ricolinostat, crizotinib or 
both. One-way ANOVA: * p < 0.05. Each experiment was repeated three times. (H) Western 
blot analysis of PARP, C-caspase-3, total MET and phosphorylated MET (p-MET) in 
NuDUL-1 and Toledo cells treated as previously described. GAPDH served as a loading 
control. NC = negative control. 
 
Figure 6. HDAC6 promotes tumor growth, and combined crizotinib and ricolinostat 
treatment produces synergistic effects in vivo. (A) Twelve BALB/c nude mice were randomly 
assigned into two groups of 6 and injected with NuDUL-1 cells infected with 
Lenti-shHDAC6 or NC. Representative tumors were imaged to visually assess tumor growth 
(left). The average tumor volume in each group (n = 6 per group) is shown as a function of 
time (right). The p value was calculated using a two-tailed Student’s t test. ** p < 0.01. (B) 
Immunostaining for the proliferation marker Ki-67 and conventional H&E staining (left) in 
tissues from DLBCL xenograft mice treated as described in (A) (scale bar = 20 μm). 
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Quantification of Ki-67-positive lesions in tissues from the NC group and the shHDAC6 
group (right). ** p < 0.01. (C) Lenti.HDAC6- or NC-infected OCI-LY8 cells were 
subcutaneously implanted into BALB/c nude mice (n = 6 per group), and the tumor growth 
was assessed as described in (A). ** p < 0.01. (D) Immunostaining for the proliferation 
marker Ki-67 and conventional H&E staining in tissues from DLBCL xenograft mice 
implanted with OCI-LY8 cells infected with Lenti.HDAC6 or NC (scale bar = 20 μm). 
Quantification of Ki-67-positive lesions in tissues from the NC group and the HDAC6 group. 
** p < 0.01. NuDUL-1 cells not subjected to treatment were used to produce xenografts, and 
when tumors reached 68–185 mm2 in size, the mice were grouped (n = 6 per group) and 
treated for 18 days as follows: crizotinib and ricolinostat (50 mg per kg body weight) were 
provided through daily oral gavage, and crizotinib combined with ricolinostat was 
administered. (E) The effects of treatment with vehicle, crizotinib, ricolinostat or combination 
on tumor growth in NuDUL-1 xenografts were monitored according to the tumor DT and 
tripling time (TT). One-way ANOVA: ** p < 0.01. (F) Representative tumors were imaged 
after sacrifice to visually assess the efficacy of crizotinib, ricolinostat or the combination 
treatment on the tumor growth of NuDUL-1 xenografts in mice. At the final time point, the p 
value was calculated through one-way ANOVA: *** p < 0.001. (G) Western blot analyses 
confirmed a reduction of MET phosphorylation after the combination treatment with 
crizotinib and ricolinostat. GAPDH served as a loading control. Error bars show SD. NC = 
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